Replimune (REPL) announced that it has submitted a biologics license application, or BLA, to the FDA for RP1 in combination with nivolumab for the treatment of adult patients with advanced melanoma ...
Jaguar is rebranding itself, announcing a "new era" in an ethos tracing back to its founder, Sir William Lyons.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback